2021
DOI: 10.3390/pharmaceutics13070977
|View full text |Cite|
|
Sign up to set email alerts
|

RETRACTED: Development and Optimization of Luliconazole Spanlastics to Augment the Antifungal Activity against Candida albicans

Abstract: Luliconazole is a new topical imidazole antifungal drug for the treatment of skin infections. It has low solubility and poor skin penetration which limits its therapeutic applications. In order to improve its therapeutic efficacy, spanlastics nanoformulation was developed and optimized using a combined mixture-process variable design (CMPV). The optimized formulation was converted into a hydrogel formula to enhance skin penetration and increase the efficacy in experimental cutaneous Candida albicans infections… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 29 publications
1
5
0
Order By: Relevance
“…Apart from invasive infections, the in vivo efficacy of S -F24 against C. albicans skin infections in mice was also evaluated using luliconazole (Luli) as the positive control. , As shown in Figure A, an aggravated wound was observed in the saline group (control) on day 5 after infection with C. albicans 5314.…”
Section: Resultsmentioning
confidence: 99%
“…Apart from invasive infections, the in vivo efficacy of S -F24 against C. albicans skin infections in mice was also evaluated using luliconazole (Luli) as the positive control. , As shown in Figure A, an aggravated wound was observed in the saline group (control) on day 5 after infection with C. albicans 5314.…”
Section: Resultsmentioning
confidence: 99%
“…Alhakamy et al developed luliconazole loaded spanlastics to enhance the antifungal activity of the drug against Candida albicans [52]. Luliconazole is a new imidazole antifungal drug that treats skin infections.…”
Section: Spanlasticsmentioning
confidence: 99%
“…NEs, as ocular applications, offer ease of application, less frequent instillation and enhanced ocular bioavailability. Currently the nanoformulations or nanostructure carriers for luliconazole include nanoemulgel [ 27 ], spanlastic nanocarriers [ 28 , 29 ], nanostructured lipid carriers (NLCs) [ 30 , 31 ], niosomal gel-based systems [ 32 ], luliconazole-based SLN gel for vaginal infection [ 33 ], lyotropic liquid crystalline nanoparticles [ 34 ], vesicular-based gel formulations [ 19 ] and nanocrystal-loaded hydrogels [ 35 ]. These studies about the delivery of luliconazole mainly focused on cutaneous application or vaginal application, and the results demonstrated improved cutaneous permeation.…”
Section: Introductionmentioning
confidence: 99%